Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación

Monitoring hepatitis C virus treatment rates in an Opioid Treatment Program, A longitudinal study

  • Sanvisens, Arantza|||0000-0001-6269-5491
  • Rivas, Inmaculada|||0000-0003-2633-5530
  • Faure, Eva|||0000-0002-5056-0888
  • Espinach, Néstor|||0000-0002-5726-5435
  • Hernandez Rubio, Anna|||0000-0001-8612-7827
  • Majó, Xavier|||0000-0003-4338-6014
  • Colom Farran, J.|||0000-0001-6861-7865
  • Muga, Roberto|||0000-0001-6301-431X
Direct-acting antivirals (DAAs) are recommended for the treatment of hepatitis C virus (HCV) infection in patients treated with methadone or buprenorphine. To assess HCV treatment rates in an Opioid Treatment Program (OTP). This longitudinal study included 501 patients (81.4% men, median age: 45 years; interquartile range: 39-50 years) enrolled in an OTP between October 2015 and September 2017. Patients were followed until September 2019. Data on socio-demographics, substance use, HCV infection, human immunodeficiency virus (HIV) infection and laboratory parameters were collected at entry. We analyzed medical records to evaluate HCV treatment. Kaplan-Meier methods and Cox regression models were used to analyze the DAA treatment uptake and to identify treatment predictors. Prevalence of HCV and HIV infection was 70% and 34%, respectively. Among anti-HCV-positive (n = 336) patients, 47.2%, 41.3%, and 31.9% used alcohol, cannabis, and cocaine, respectively. HCV-RNA tests were positive in 233 (69.3%) patients. Twentyeight patients (8.3%) cleared the infection, and 59/308 (19.1%) had received interferon-based treatment regimens before 2015. Among 249 patients eligible, 111 (44.6%) received DAAs. Treatment rates significantly increased over time from 7.8/100 person-years (p-y) (95%CI: 5.0-12.3) in 2015 to 18.9/100 p-y (95%CI: 11.7-30.3) in 2019. In a multivariate analysis, patients with HIV co-infection were twice as likely to receive DAAs (HR = 1.94, 95%CI: 1.21-3.12) than patients with HCV mono-infection. Current drug use was an independent risk factor for not receiving treatment against infection (HR = 0.48, 95%CI: 0.29-0.80). HCV treatment is evolving in patients with HCV-HIV co-infection. Ongoing drug use while in an OTP might negatively impact the readiness to treat infection.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Assessment of liver disease in patients with chronic hepatitis C and unhealthy alcohol use

  • Fuster, Daniel|||0000-0003-1262-5860
  • García Calvo, Xavier|||0000-0001-8165-8717
  • Zuluaga Blanco, Yenny Paola|||0000-0002-0247-0351
  • Bolao, Ferran|||0000-0002-9104-6615
  • Muga, Roberto|||0000-0001-6301-431X
Hepatitis C virus (HCV) infection and unhealthy alcohol use are major drivers of the burden of liver disease worldwide and commonly co-occur. Assessment of underlying liver damage is a cornerstone of the clinical care of patients with chronic HCV infection and/or unhealthy alcohol use because many of them are diagnosed at advanced stages of disease. Early diagnosis of liver disease before decompensated liver cirrhosis becomes established is essential for treatment with direct acting antivirals and/or abstinence from alcohol consumption, which are the main therapeutic approaches for clinical management. In this review, we discuss current knowledge around the use of non-invasive methods to assess liver disease, such as abdominal ultrasound, controlled attenuation parameter, transient elastography, magnetic resonance imaging, and indices based on serum markers of liver injury.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Plasma concentrations of granulocyte colony-stimulating factor (G-CSF) in patients with substance use disorders and comorbid major depressive disorder

  • Galván, Sandra Torres
  • Flores-López, María|||0000-0003-3489-1465
  • Romero-Sanchiz, Pablo
  • Requena-Ocaña, Nerea|||0000-0003-3257-8459
  • Porras-Perales, Oscar
  • Nogueira-Arjona, Raquel
  • Mayoral-Cleries, Fermín
  • Araos, Pedro|||0000-0001-5172-8796
  • Serrano, Antonia
  • Muga, Roberto|||0000-0001-6301-431X
  • Pavón, Francisco Javier
  • García Marchena, Nuria|||0000-0002-0575-3613
  • de Fonseca, Fernando Rodríguez
Granulocyte colony-stimulating factor (G-CSF) has raised much interest because of its role in cocaine addiction in preclinical models. We explored the plasma concentrations of G-CSF in patients diagnosed with substance use disorder (SUD) and highly comorbid psychiatric disorders. In particular, we investigated the association between G-CSF concentrations and comorbid major depressive disorder (MDD) in patients with cocaine and alcohol use disorders (CUD and AUD, respectively). Additionally, patients with MDD but not SUD were included in the study. Three hundred and eleven participants were enrolled in this exploratory study: 136 control subjects, 125 patients with SUD (SUD group) from outpatient treatment programs for cocaine (N = 60, cocaine subgroup) and alcohol (N = 65, alcohol subgroup), and 50 patients with MDD but not SUD (MDD group) from primary-care settings. Participants were assessed based on DSM-IV-TR criteria, and a blood sample was collected to examine the plasma concentrations of G-CSF. G-CSF concentrations were negatively correlated with age in the entire sample (r = - 0.233, p < 0.001) but not in the patients with MDD. G-CSF concentrations were lower in patients with SUD than in controls (p < 0.05), specifically in the cocaine subgroup (p < 0.05). Patients with SUD and comorbid MDD had lower G-CSF concentrations than patients with SUD but not comorbid MDD or controls (p < 0.05). In contrast, patients with MDD but not SUD showed no differences compared with their controls. The negative association between G-CSF concentrations and age in the sample was not observed in patients with MDD. G-CSF concentrations were decreased in patients with SUD and comorbid MDD but not in patients with MDD. Therefore, G-CSF may be useful to improve the stratification of patients with dual diagnosis seeking treatment. Further investigation is needed to explore the impact of sex and type of drug on the expression of G-CSF.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Vascular Endothelial Growth Factor as a Potential Biomarker of Neuroinflammation and Frontal Cognitive Impairment in Patients with Alcohol Use Disorder

  • Requena-Ocaña, Nerea|||0000-0003-3257-8459
  • Flores-López, María|||0000-0003-3489-1465
  • Papaseit, Esther|||0000-0003-2620-4274
  • García Marchena, Nuria|||0000-0002-0575-3613
  • Ruiz, Juan Jesús
  • Ortega-Pinazo, Jesús
  • Serrano, Antonia
  • Pavón-Morón, Francisco Javier|||0000-0002-5256-8904
  • Farré Albaladejo, Magí|||0000-0001-8338-7543
  • Suarez, Juan|||0000-0001-5254-9802
  • Rodríguez de Fonseca, Fernando|||0000-0002-4516-5795
  • Araos, Pedro|||0000-0001-5172-8796
(1) Background: Alcohol Use Disorder (AUD) is associated with functional disruption of several brain structures that may trigger cognitive dysfunction. One of the mechanisms of alcohol-associated cognitive impairment has been proposed to arise from its direct impact on the immune system, which culminates in the release of cytokines and chemokines which can eventually reach the brain. Alcohol can also disrupt the blood-brain barrier, facilitating the penetration of pro-inflammatory molecules throughout vascular endothelial growth factor A (VEGFA). Thus, alcohol-induced alterations in chemokines and VEGFA might contribute to the neuroinflammation and cognitive impairment associated with AUD. (2) Methods: The present cross-sectional study investigates whether patients with AUD (n = 86) present cognitive disability associated to alterations in plasma concentration of SDF-1, fractalkine, eotaxin, MCP-1, MIP-1α and VEGFA when compared to control subjects (n = 51). (3) Results: The analysis indicated that SDF-1 and MCP-1 concentrations were higher in AUD patients than in controls. Concentrations of VEGFA were higher in AUD patients with severe frontal deficits, and the score of frontal lobe functions was negatively correlated with VEGFA and fractalkine. Acute alcohol effects on VEGFA plasma levels in healthy volunteers demonstrated the induction of VEGFA release by heavy alcohol drinking. VEGFA was positively correlated with pro-inflammatory chemokines in AUD patients with frontal cognitive impairment. (4) Conclusions: we propose VEGFA/chemokine monitoring as biomarkers of potential cognitive impairment in AUD patients.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Plasma Amino Acid Concentrations in Patients with Alcohol and/or Cocaine Use Disorders and Their Association with Psychiatric Comorbidity and Sex

  • García Marchena, Nuria|||0000-0002-0575-3613
  • Marcos, Alberto
  • Flores-López, María|||0000-0003-3489-1465
  • Moreno-Fernández, Mario
  • Requena-Ocaña, Nerea|||0000-0003-3257-8459
  • Porras-Perales, Oscar
  • Torres-Galván, Sandra
  • Araos, Pedro|||0000-0001-5172-8796
  • Serrano, Antonia
  • Muga, Roberto|||0000-0001-6301-431X
  • Ruiz-Ruiz, Juan Jesús|||0000-0001-8692-4463
  • Rodríguez de Fonseca, Fernando|||0000-0002-4516-5795
  • Ambrosio, Emilio
  • Pavón-Morón, Francisco Javier|||0000-0002-5256-8904
(1) Background: Co-occurrence of mental and substance use disorders (SUD) is prevalent, but complicates their clinical courses, and specific biomarkers are required. Amino acids are altered in primary mental disorders; however, little is known about SUD and psychiatric comorbidity. Because most psychiatric disorders and biomarkers show sex differences, we investigated amino acids in men and women with alcohol and/or cocaine use disorders (AUD and/or CUD) and psychiatric comorbidity. (2) Methods: A cross-sectional study was conducted in 295 participants, who were divided into four groups (AUD, n = 60; CUD, n = 41; AUD + CUD, n = 64; and control, n = 130). Participants were clinically assessed, and plasma amino acid concentrations were analyzed in relation to sex, diagnosis of SUD and psychiatric comorbidity (3) Results: In the total sample, there were sex differences, and women showed lower Iso, Leu, Gln and Glu than men. While patients with CUD and AUD + CUD had higher Glu, Gly, Orn and Ser than controls, patients with AUD showed no differences. In SUD, patients with psychiatric comorbidity had lower Orn and higher Ala than non-comorbid patients in the AUD group. (4) Conclusions: There was a dysregulation of plasma amino acids in abstinent patients with SUD. However, our results suggest the importance of considering the clinical characteristics and sex in the validity of amino acids as potential biomarkers for SUD.